BioCryst Pharmaceuticals
BioCryst Pharmaceuticals' revenue rose 94.1% to $875 million in fiscal 2025. Its operating margin was 39.0%, up from −0.6% a year earlier. Free cash flow was $345 million. The diluted share count rose 5.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What BioCryst Pharmaceuticals does
BioCryst develops and sells medicines for hereditary angioedema, or HAE, and other rare diseases. HAE is an inherited condition that causes sudden swelling attacks. Its main product, ORLADEYO (berotralstat), is a once-daily capsule that prevents HAE attacks. The company says it discovered and developed it internally. It is approved in the United States and several other markets, and a pellet form for children aged 2 to under 12 is approved in the United States.
BioCryst earns revenue from selling ORLADEYO and also sells RAPIVAB, an intravenous flu treatment. It has a partnership with Torii. Its pipeline includes navenibart, an injectable antibody for HAE that it gained by merging with Astria Therapeutics, and early-stage candidates for Netherton syndrome, diabetic macular edema and atopic dermatitis.
The company says it wants to use its sales infrastructure to commercialize more rare disease medicines, whether it finds them itself or gets them through business deals.
Its biggest risks, as it describes them
- It may not reach sustained profitability.
- It may need to raise more money and could have trouble doing so.
- The Astria merger may be harder, costlier or slower to combine than expected, and may not bring the hoped-for benefits.
- Its drug candidates may not win or keep regulatory approval.
- Generic or biosimilar competition could cut into the sales of its medicines.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 508 | 424 | 389 | 321 | 275 |
| Debt incl. finance leases | 298 | 234 | 308 | 319 | 3 |
| Net debt (negative means net cash) | −210 | −190 | −81 | −2 | −272 |
| Net debt to EBITDA | — | — | — | — | −0.8x |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3.0x | −1.5x | −1.0x | −0.0x | 4.3x |
| Current ratio | 5.5x | 4.9x | 3.3x | 2.6x | 2.1x |
| Quick ratio | 5.3x | 4.6x | 3.1x | 2.6x | 2.0x |
Cash flow
Projections
Project BioCryst Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What BioCryst Pharmaceuticals says to expect
- Full year 2026: revenue
The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB ® (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million.
- Full year 2026: non-GAAP operating expenses
The company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $415 million to $425 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought BioCryst Pharmaceuticals shares on the open market, and 3 insiders sold $4.1 million, $3.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 18, 2026 | Amy E McKeeDirector | Sold | 11,180 | $8.97 | $100,285 | Form 4 |
| May 13, 2026 | Alane P BarnesChief Legal Officer | Sold plan | 62,500 | $9.54 | $596,250 | Form 4 |
| Mar 20, 2026 | Theresa HeggieDirector | Sold | 49,933 | $10.11 | $504,823 | Form 4 |
| Mar 16, 2026 | Alane P BarnesChief Legal Officer | Sold plan | 150,000 | $9.15 | $1.4 million | Form 4 |
| Dec 22, 2025 | Alane P BarnesChief Legal Officer | Sold plan | 21,773 | $7.65 | $166,563 | Form 4 |
| Dec 15, 2025 | Alane P BarnesChief Legal Officer | Sold plan | 21,210 | $7.65 | $162,256 | Form 4 |
| Dec 3, 2025 | Alane P BarnesChief Legal Officer | Sold plan | 19,770 | $7.65 | $151,240 | Form 4 |
| Dec 2, 2025 | Alane P BarnesChief Legal Officer | Sold plan | 50,906 | $7.21 | $367,032 | Form 4 |
| Dec 1, 2025 | Alane P BarnesChief Legal Officer | Sold plan | 91,004 | $7.10 | $646,128 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 3 of 9 | 7 of 9 |
| Rule of 40 | −7.0% | 24.2% | 133.5% |
| Altman Z'' | −8.05 | −8.82 | −2.63 |
| Accruals ratio | −24.6% | −7.3% | −16.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 3 of 9 | 7 of 9 |
Compare
Put BioCryst Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals | FY25 | 94.1% | 39.0% | 39.4% | — | −0.8x | 7 | |
| Harmony Biosciences | FY25 | 21.5% | 24.0% | 40.1% | 48.9% | — | 5 | Compare |
| Repligen | FY25 | 16.4% | 7.5% | 12.7% | 2.4% | −1.7x | — | Compare |
| Novavax | FY25 | 64.7% | 40.3% | −22.3% | — | −1.0x | 5 | Compare |
| TG Therapeutics | FY25 | 87.3% | 20.0% | −4.0% | 29.0% | 0.4x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 26 | 25 | 21 | 49 | 18 | 157 | 271 | 331 | 451 | 875 |
| Revenue growth | −45.4% | −4.4% | −18.0% | 136.4% | −63.5% | 782.4% | 72.3% | 22.4% | 36.0% | 94.1% |
| Gross profit | 24 | 24 | — | 45 | 16 | 150 | 264 | 327 | 438 | 856 |
| Research and development | 61 | 67 | 85 | 107 | 123 | 209 | 253 | 217 | 175 | 166 |
| Operating income | −49 | −57 | −94 | −100 | −175 | −178 | −148 | −104 | −2 | 341 |
| Net income | −55 | −66 | −101 | −109 | −183 | −184 | −247 | −226 | −89 | 264 |
| Diluted EPS (US$) | −0.75 | −0.78 | −0.98 | −940.00 | −1.09 | −1.03 | −1.33 | −1.18 | −0.43 | 1.21 |
| Diluted shares (millions) | 74 | 84 | 103 | 116 | 167 | 179 | 186 | 192 | 207 | 219 |
| Cash flow | ||||||||||
| Cash from operations | −53 | −41 | −93 | −90 | −135 | −142 | −162 | −95 | −52 | 347 |
| Capital expenditure | 5 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 2 |
| Free cash flow | −59 | −41 | −93 | −90 | −136 | −145 | −163 | −97 | −53 | 345 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 13 | 9 | 18 | 15 | 35 | 45 | 56 | 65 | 85 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 55 | 114 | 104 | 136 | 300 | 508 | 424 | 389 | 321 | 275 |
| Debt incl. finance leases | 23 | 23 | 33 | 55 | 128 | 298 | 234 | 308 | 319 | 3 |
| Total assets | 90 | 178 | 147 | 175 | 335 | 588 | 550 | 517 | 490 | 514 |
| Total liabilities | 88 | 94 | 98 | 137 | 354 | 695 | 845 | 972 | 966 | 633 |
| Shareholders' equity | 2 | 84 | 49 | 38 | −19 | −107 | −295 | −456 | −476 | −119 |
| Margins and ratios | ||||||||||
| Gross margin | 91.3% | 95.5% | — | 92.4% | 91.3% | 95.4% | 97.6% | 98.7% | 97.3% | 97.8% |
| Operating margin | −184.4% | −227.9% | −456.2% | −203.7% | −981.1% | −113.1% | −54.8% | −31.3% | −0.6% | 39.0% |
| Net margin | −209.2% | −261.2% | −490.2% | −223.0% | −1,026.3% | −117.1% | −91.2% | −68.4% | −19.7% | 30.2% |
| Free cash flow margin | −222.8% | −164.7% | −450.0% | −184.1% | −761.4% | −92.0% | −60.3% | −29.4% | −11.8% | 39.4% |
| Rule of 40 (growth + FCF margin) | −268.2% | −169.1% | −468.0% | −47.7% | −824.9% | 690.4% | 12.1% | −7.0% | 24.2% | 133.5% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −223.7% | −154.2% | −152.3% | −248.9% | — | — | — | — | — | — |
| Return on assets | −52.0% | −49.1% | −62.3% | −67.6% | −71.7% | −39.9% | −43.4% | −42.5% | −17.6% | 52.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | −0.8x |